Improving Beta-thalassemia Outcomes - Baseline Assessment
Launch Date:
September 23, 2021
September 23, 2021
The following questions are designed to assess your knowledge and practice of patients with Beta-thalassemia.
Sujit Sheth, MD
Chief, Division of Pediatric Hematology/Oncology
Vice Chair of Clinical Research, Department of Pediatrics
Professor of Clinical Pediatrics, Department of Pediatrics
Weill Cornell Medical Center
Attending Pediatrician
New York-Presbyterian Komansky Children's Hospital
New York, NY
Dr. Sujit Sheth is the Chief of the Division of Pediatric Hematology/Oncology and Professor of Clinical Pediatrics at Weill Cornell Medicine and an Attending Pediatrician at NewYork-Presbyterian Phyllis and David Komansky Children's Hospital and Weill Cornell Medical Center. He is also Vice Chair of Clinical Research in the Department of Pediatrics at Weill Cornell Medicine. Dr. Sheth is board-certified in pediatrics and pediatric hematology/oncology, and is an expert in iron metabolism, thalassemia, and sickle cell disease.Dorothy Kleinert, DNP, MPH, MA, ANP, CPNP
Pediatrics – Thalassemia Clinical Research
Weill Cornell Medicine
New York, NY
Dorothy Kleinert received her Doctor of Nursing Practice (DNP) degree at Case Western Reserve University and her Pediatric Nurse Practitioner (PNP) degree at New York University, where she also received her MA degree in Adult Primary Care. She has also completed her Master of Public Health degree (MPH) at Columbia University.1.
Discuss the underlying pathophysiology of β-thalassemia as it relates to clinical presentation and outcomes.
2.
Apply evidence- and guideline-based recommendations for the recognition and management of β-thalassemia–related transfusion issues.
3.
Incorporate efficacy and safety data in novel approaches in treating β-thalassemia including erythroid maturation agents and gene therapies.
4.
Apply best practices to transition pediatric patients with β-thalassemia smoothly and safely to adult care.
